We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Effect of Adding an Initial Dose of Mitomycin C into the Vesicular Delayed Six-Week Treatment in Patients with Superficial Bladder Cancer.
- Authors
Tadayon, Farhad; Mazdak, Hamid; Sarrafian, Mahmoud; Hadi, Mazaher; Mirhashemi, Sayed Mojtaba; Khorrami, Mohammad Hatef
- Abstract
Introduction: Bladder tumors have a high incidence. Despite most of them are superficial their relapse rate after Transurethral resection of bladder tumor (TURBT) surgery is high. Treatment after TURBT by in-vesicular methods is a way to decrease the relapse rate. The purpose of this study was to determine the effect of an added dose of Mitomycin in addition of the delayed six-weeks treatment on the rate and degree of tumor relapse in patients with bladder tumor referred to Alzahra and Noor hospitals in Isfahan. Methods: In this prospective study, patients with superficial bladder tumors were selected and randomly devided in two groops. The sample size for each group was 18 patients. Patients in case group received a dose of mitomycin C after TURBT; then, both groups underwent delayed six-week treatment. Results in terms of numbers, time, grade, and stage of relapse were analyzed using χ², Mann-Whitney, and Student t-test. Finding: The recurrence was seen in 33.3% of patients in case group and 66.7% of control groop (P = 0.04). The grade of relapsed tumor was significantly difference between the two groups (P = 0.001). The mean frequency of relapse was 0.5 ± 0.78 in case group and 1.1 ± 1.0 in control group (P = 0.04). The type T1 is more prevalent in control groop in comparison to case groop (P = 0.006) but the time of relapse was not significantly difference between groups (P = 0.09). The relapse time was 12.5 ± 14.1 months in case group and 6.7 ± 3.7 months in control group. Conclusion: Considering the reduced number, stage, and grade of relapse in case group, the positive effect of using Mitomycin immediately after TURBT was proved. Studies with more patients and further follow-up period are necessary to review late relapses.
- Subjects
ISFAHAN (Iran); IRAN; BLADDER cancer; MITOMYCIN C; TRANSURETHRAL prostatectomy; CANCER patients; IMMUNOSUPPRESSIVE agents
- Publication
Journal of Isfahan Medical School, 2011, Vol 28, Issue 121, p1
- ISSN
1027-7595
- Publication type
Article